Mindfulness meditation training effects on CD4+ T lymphocytes in HIV-1 infected adults: a small randomized controlled trial.

TitleMindfulness meditation training effects on CD4+ T lymphocytes in HIV-1 infected adults: a small randomized controlled trial.
Publication TypeJournal Article
Year of Publication2009
AuthorsJ Creswell D, Myers HF, Cole SW, Irwin MR
JournalBrain Behav Immun
Volume23
Issue2
Pagination184-8
Date Published2009 Feb
ISSN1090-2139
KeywordsAdult, CD4-Positive T-Lymphocytes, Female, Follow-Up Studies, HIV Infections, HIV-1, Humans, Male, Meditation, Middle Aged, Stress, Psychological, Time Factors, Treatment Outcome
Abstract

UNLABELLED: Mindfulness meditation training has stress reduction benefits in various patient populations, but its effects on biological markers of HIV-1 progression are unknown. The present study tested the efficacy of an 8-week Mindfulness-based stress reduction (MBSR) meditation program compared to a 1-day control seminar on CD4+ T lymphocyte counts in stressed HIV infected adults. A single-blind randomized controlled trial was conducted with enrollment and follow-up occurring between November 2005 and December 2007. A diverse community sample of 48 HIV-1 infected adults was randomized and entered treatment in either an 8-week MBSR or a 1-day control stress reduction education seminar. The primary outcome was circulating counts of CD4+ T lymphocytes. Participants in the 1-day control seminar showed declines in CD4+ T lymphocyte counts whereas counts among participants in the 8-week MBSR program were unchanged from baseline to post-intervention (time x treatment condition interaction, p=.02). This effect was independent of antiretroviral (ARV) medication use. Additional analyses indicated that treatment adherence to the mindfulness meditation program, as measured by class attendance, mediated the effects of mindfulness meditation training on buffering CD4+ T lymphocyte declines. These findings provide an initial indication that mindfulness meditation training can buffer CD4+ T lymphocyte declines in HIV-1 infected adults.

CLINICAL TRIALS REGISTRATION: clinicaltrials.gov, Identifier: NCT00600561.

DOI10.1016/j.bbi.2008.07.004
Alternate JournalBrain Behav. Immun.
PubMed ID18678242
PubMed Central IDPMC2725018
Grant ListM01 RR000827 / RR / NCRR NIH HHS / United States
M01 RR000827-230697 / RR / NCRR NIH HHS / United States
M01 RR000865 / RR / NCRR NIH HHS / United States
M01 RR000865-358125 / RR / NCRR NIH HHS / United States
M01 RR000865-358141 / RR / NCRR NIH HHS / United States
M01-RR00865 / RR / NCRR NIH HHS / United States
P30 AG028748 / AG / NIA NIH HHS / United States
P30 AG028748-049004 / AG / NIA NIH HHS / United States
R01 AG026364 / AG / NIA NIH HHS / United States
R01 AG026364-05 / AG / NIA NIH HHS / United States
R01 CA119159 / CA / NCI NIH HHS / United States
R01 CA119159-04 / CA / NCI NIH HHS / United States
R01 HL079955 / HL / NHLBI NIH HHS / United States
R01 HL079955-04 / HL / NHLBI NIH HHS / United States
T32 MH019925 / MH / NIMH NIH HHS / United States
T32 MH019925-09 / MH / NIMH NIH HHS / United States
T32 MH019925-12 / MH / NIMH NIH HHS / United States
T32MH-019925-09 / MH / NIMH NIH HHS / United States